Following an FDA approval last year based on a tumor progression benefit, AstraZeneca said Monday that its Tagrisso combination with chemotherapy extended patients’ lives compared with Tagrisso alone in first-line EGFR-mutated NSCLC. More: AstraZeneca, facing lung cancer challenge from J&J,
read more
Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients More: AlzeCure to present promising pain therapy ACD440 at NeuPSIG 2025 Source: News
read more
EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics More: Ezmekly becomes first approved EU therapy for NF1-PN in children and adults Source: News
read moreThe overwhelmingly negative vote came as a bit of a surprise given that several experts hinted that the combo may potentially be effective. More: Lundbeck, Otsuka's PTSD bid for Rexulti dealt a setback at FDA advisory committee Source: fierce
read moreSince starting operations in North Carolina 30 years ago, Biogen has spent approximately $10 billion to bolster its manufacturing presence in the Tar Heel state. But that’s not enough for the Massachusetts-based biotech, which says it will spend $2 billion
read moreGeorge Tidmarsh, M.D., Ph.D., will head up the FDA’s Center for Drug Evaluation and Research after a lengthy career in academia and drug development. More: FDA names next CDER director in biotech vet George Tidmarsh Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals